Key result
Adrenocorticotropic hormone as initial treatment for infantile spasms in children with Down syndrome achieved 94.1% remission at 3 months compared with 35.3% for other treatments.
Why the study?
To evaluate infantile spasms in children with Down syndrome, assess treatment efficacy and treatment lag, and identify risk factors predicting their occurrence in this population.
Does adrenocorticotropic hormone improve remission rates of infantile spasms in children with Down syndrome compared to other first-line treatments?
Observational (n=37)
No
Does adrenocorticotropic hormone improve remission rates of infantile spasms in children with Down syndrome compared to other first-line treatments?
Absolute Event Rate: 94.1% vs 35.3%
Adrenocorticotropic hormone is highly effective as an initial treatment for infantile spasms in children with Down syndrome, achieving significantly higher remission rates than other first-line treatments.
May signal diagnostic delays in Down syndrome; leaves open whether earlier screening improves outcomes.
Objectives. To evaluate infantile spasms in children with Down syndrome including assessment of efficacy of treatments, presence of treatment lag, and to identify risk factors that may predict the occurrence of infantile spasms in this population. Methods. Medical charts, electroencephalograms, and brain magnetic resonance images were evaluated in 37 children treated for infantile spasms at a single institution from 2005 to 2015. Results. Mean age at diagnosis was 9.16 months, with an average 1.38-month lag from spasms onset to start of medication. Prevalence of heart defects and pulmonary hypertension were significantly higher in those with infantile spams compared with those without. Eighty-one percent receiving adrenocorticotropic hormone as initial treatment experienced remission within 2 weeks, 94.1% had remission at 3 months compared with 18.8% at 2 weeks and 35.3% at 3 months for other first-line treatments. Type of treatment was the only predictor of good outcome. Conclusions. Results stress the importance of early recognition and adrenocorticotropic hormone treatment for this seizure disorder in children with Down syndrome.
No takes yet. Share an insight, caveat, or question.
Daniels et al. (2019) conducted an observational in Infantile spasms in children with Down syndrome (n=37). Adrenocorticotropic hormone vs. Other first-line treatments was evaluated on Remission at 3 months. Adrenocorticotropic hormone as initial treatment for infantile spasms in children with Down syndrome achieved 94.1% remission at 3 months compared with 35.3% for other treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: